BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- Myeloma Service
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 130 patients (estimated)
- Sponsors
- Juno Therapeutics, a Bristol-Myers Squibb Company
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA), GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1819
- NCT Identifier
- NCT06153251
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.